132945-75-6

Usage

Uses

Used in Pharmaceutical Industry:
1-Pyrrolidinecarboxylic acid, 3-[(methylsulfonyl)oxy]-, 1,1-dimethylethyl ester, (3S)is used as an intermediate compound for the synthesis of various pharmaceutical products. Its unique structure and chirality make it a valuable building block in the development of new drugs with specific therapeutic properties.
Used in Chemical Industry:
1-Pyrrolidinecarboxylic acid, 3-[(methylsulfonyl)oxy]-, 1,1-dimethylethyl ester, (3S)is used as a reagent or catalyst in various chemical reactions. Its functional groups, such as the carboxylic acid and methylsulfonyl groups, can participate in a range of chemical transformations, making it a versatile component in the synthesis of other complex molecules.
Used in Research and Development:
1-Pyrrolidinecarboxylic acid, 3-[(methylsulfonyl)oxy]-, 1,1-dimethylethyl ester, (3S)is used as a research compound in academic and industrial laboratories. Its unique structure and properties make it an interesting subject for studies in organic chemistry, materials science, and other related fields, potentially leading to new discoveries and applications.

Upstream product

• 124-63-0 methanesulfonyl chloride 
• 101469-92-5 (S)-3-hydroxy-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 24424-99-5 di-tert-butyl dicarbonate 
• 40499-83-0 (3R)-pyrrolidinol 
• 133955-86-9 N-tert-butoxycarbonyl-(S)-pyrrolidinol 
• 118354-71-5 (S)-methanesulfonic acid 1-benzylpyrrolidin-3-yl ester 
• 960508-08-1 N,N-diethyl-1,2,3,3,3-pentafluoropropylimidium methanesulfonate 
• 109431-87-0 (R)-tert-butyl 3-hydroxypyrrolidine-1-carboxylate 
• 960508-07-0 tetramethyl-2-fluoroformamidinium methanesulfonate 
• 960508-04-7 2-fluoro-1,3-dimethylimidazolinium methanesulfonate 
• 101385-90-4 (S)-N-benzyl-3-hydroxypyrrolidine 

Downstream Products

• 132945-76-7 tert-butyl (3R)-3-cyano-1-pyrrolidinecarboxylate 
• 125552-56-9 (S)-tert-butyl 3-azidopyrrolidine-1-carboxylate 
• 147081-49-0 (R)-3-aminopyrrolidine-1-carboxylic acid tert-butyl ester 
• 960401-43-8 (R)-tert-butyl 3-(4-amino-2-methoxyphenoxy)pyrrolidine-1-carboxylate 
• 1574542-90-7 (R)-tert-butyl 3-(4-(3-(4-cyclopropylphenoxy)-2-oxo-2,5-dihydro-1H-pyrrol-1-yl)-2-methoxyphenoxy)pyrrolidine-1-carboxylate 
• 960401-35-8 (R)-tert-butyl 3-(2-methoxy-4-nitrophenoxy)pyrrolidine-1-carboxylate 
• 1332712-38-5 4-[2-((R)-1-tert-Butoxycarbonyl-pyrrolidin-3-yloxy)-4-fluoro-phenylamino]-5-methyl-thieno[2,3-d]pyrimidine-6-carboxylic acid methyl ester 
• 1204419-23-7 (R)-(3,5-Dinitrophenyl)(3-(4-methoxyphenylamino)pyrrolidin-1-yl)methanone 
• 1204421-38-4 C₁₆H₂₄N₂O₃ 
• 1189753-52-3 (S)-2,2-diphenyl-2-[1-(tert-butyloxycarbonyl)-3-pyrrolidinyl]acetonitrile 
• 1227622-55-0 3-(4-chloro-2-formyl-phenoxy)-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 1221743-88-9 (R)-tert-butyl 3-(4-amino-3-(4-nitrophenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)pyrrolidine-1-carboxylate 
• 143700-04-3 (R)-tert-butyl 3-azidopyrrolidine-1-carboxylate 
• 960529-75-3 benzophenone O-[(R)-N-tert-butoxycarbonyl-3-pyrrolidinyl]oxime 

Relevant academic research and scientific papers

ISOQUINOLINE DERIVATIVES AS SIK2 INHIBITORS

Provided are compounds of the Formula I, and salts and solvates thereof: (I) wherein R1, R2, R3, R6, X1, X2 and Z are defined in the specification. The compounds are inhibitors of salt-inducible kinase (SIK), particular SIK2, and are useful in therapy, particularly in the treatment of a proliferative disorder, a benign neoplasm, pathological angiogenesis, an inflammatory disease or condition, a musculoskeletal disease or condition, an autoimmune disease, a haematological disease or condition, a neurological disease or condition, a psychiatric disorder, or a metabolic disorder.

ISOQUINOLINE DERIVATIVES AS SIK2 INHIBITORS

Provided are compounds of the Formula I, and salts and solvates thereof: (I) wherein R1, R2, R3, X1, X2, X3 and Z are defined in the specification. The compounds are inhibitors of salt-inducible kinase (SIK), particular SIK2, and are useful in therapy, particularly in the treatment of a proliferative disorder, a benign neoplasm, pathological angiogenesis, an inflammatory disease or condition, a musculoskeletal disease or condition, an autoimmune disease, a haematological disease or condition, a neurological disease or condition, a psychiatric disorder, or a metabolic disorder.

6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS

The present disclosure provides 6-heteroaryloxy benzimidazole and azabenzimidazole compounds and compositions thereof useful for inhibiting JAK2.

Novel pyrrolidine or piperidine derivatives having activity for T-type calcium channel

A pyrrolidine or piperidine compound having activity for T - type calcium channel, wherein the pyrrolidine or piperidine compound of Formula 1 according to the present invention has an excellent antagonistic activity to, T-type calcium channel, and can be used as a preventive or therapeutic agent, for pain diseases, or cancer related to cancer, or cancer such as, epilepsy and,hepatic pain, angina. (by machine translation)

PYRROLO(PYRAZOLO)PYRIMIDINE DERIVATIVE AS LRRK2 INHIBITOR

The present invention relates to a pyrrolo(pyrazolo)pyrimidine derivative having efficacy as an LRRK2 inhibitor, a preparation method therefor, and a pharmaceutical composition for preventing or treating degenerative brain diseases, containing the same.

RET INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF

Provided herein are a RET inhibitor, a pharmaceutical composition thereof and uses thereof. In particular, provided is a compound having Formula (I) or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof. Provided is a pharmaceutical composition comprising the compound, and uses of the compound and pharmaceutical composition thereof for the preparation of a medicament, in particular for treatment and prevention of RET-related diseases and conditions, including cancer, irritable bowel syndrome, and/or pain associated with irritable bowel syndrome.

RET INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF

Provided herein are a RET inhibitor, a pharmaceutical composition thereof and uses thereof. In particular, provided is a compound having Formula (I) or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof. Provided is a pharmaceutical composition comprising the compound, and uses of the compound and pharmaceutical composition thereof for the preparation of a medicament, in particular for treatment and prevention of RET-related diseases and conditions, including cancer, irritable bowel syndrome, and/or pain associated with irritable bowel syndrome.

Structure-Based Design of a Bromodomain and Extraterminal Domain (BET) Inhibitor Selective for the N-Terminal Bromodomains That Retains an Anti-inflammatory and Antiproliferative Phenotype

The bromodomain and extraterminal domain (BET) family of epigenetic regulators comprises four proteins (BRD2, BRD3, BRD4, BRDT), each containing tandem bromodomains. To date, small molecule inhibitors of these proteins typically bind all eight bromodomains of the family with similar affinity, resulting in a diverse range of biological effects. To enable further understanding of the broad phenotype characteristic of pan-BET inhibition, the development of inhibitors selective for individual, or sets of, bromodomains within the family is required. In this regard, we report the discovery of a potent probe molecule possessing up to 150-fold selectivity for the N-terminal bromodomains (BD1s) over the C-terminal bromodomains (BD2s) of the BETs. Guided by structural information, a specific amino acid difference between BD1 and BD2 domains was targeted for selective interaction with chemical functionality appended to the previously developed I-BET151 scaffold. Data presented herein demonstrate that selective inhibition of BD1 domains is sufficient to drive anti-inflammatory and antiproliferative effects.

IRAK DEGRADERS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

BTK Inhibitors and uses thereof

The invention discloses a bruton's tyrosine kinase (BTK) inhibitor and use thereof. Specifically, the invention provides heteroaromatic compounds or stereoisomers, geometrical isomers, tautomers, racemates, nitrogen oxides, hydrates, solvates, metabolites and pharmaceutically acceptable salts or prodrugs thereof, and pharmaceutical compositions containing the heteroaromatic compounds; the invention also discloses use of the heteroaromatic compounds or the pharmaceutical compositions containing the heteroaromatic compounds in preparation of medicines; the medicines can be used for treating autoimmune diseases, inflammatory diseases or proliferative diseases.